It is provided a pharmaceutical composition comprising 3-beta-hydroxy-5-alpha-pregnan-20-one, at least one sterol or an ester thereof and a mixture of acylglycerols with a solid fat content of less than 25% at 25° C. and 0% at 37° C. In addition it is provided a method for preparing the pharmaceutical composition.

It is provided a pharmaceutical composition comprising 3-beta-hydroxy-5-alpha-pregnan-20-one, at least one sterol or an ester thereof and a mixture of acylglycerols with a solid fat content of less than 25% at 25° C. and 0% at 37° C. In addition it is provided a method for preparing the pharmaceutical composition.

A topical formulation comprising a Cannabis derived botanical drug product, wherein the concentration of each, cannabidiol and tetrahydrocannabinol, in the topical formulation is greater than 2 milligrams per kilogram.

A topical formulation comprising a Cannabis derived botanical drug product, wherein the concentration of each, cannabidiol and tetrahydrocannabinol, in the topical formulation is greater than 2 milligrams per kilogram.

Provided is a composition for forming a coating film directly on the skin by an electrostatic spray, the composition being capable of forming a coating film having excellent skin compatibility, adhesion, and scratch resistance, having a good feel, and being easy to peel. A composition for forming a coating film, for forming a coating film composed of fibers directly on the skin by an electrostatic spray, the composition comprising the following Components (a), (b), (c), and (d): (a) a polymer having a coating film forming ability (b) one or more volatile substances selected from the group consisting of an alcohol and a ketone (c) a plasticizer (d) a feel modifier other than Component (c).

Provided is a composition for forming a coating film directly on the skin by an electrostatic spray, the composition being capable of forming a coating film having excellent skin compatibility, adhesion, and scratch resistance, having a good feel, and being easy to peel. A composition for forming a coating film, for forming a coating film composed of fibers directly on the skin by an electrostatic spray, the composition comprising the following Components (a), (b), (c), and (d): (a) a polymer having a coating film forming ability (b) one or more volatile substances selected from the group consisting of an alcohol and a ketone (c) a plasticizer (d) a feel modifier other than Component (c).

Sustained release formulations of NMDA antagonists containing encapsulated NMDA antagonist are described herein.

Sustained release formulations of NMDA antagonists containing encapsulated NMDA antagonist are described herein.

Estrogen and progesterone replacement therapies are provided herein. Among others, the following formulations are provided herein: solubilized estradiol without progesterone; micronized progesterone without estradiol; micronized progesterone with partially solubilized progesterone; solubilized estradiol with micronized progesterone; solubilized estradiol with micronized progesterone in combination with partially solubilized progesterone; and solubilized estradiol with solubilized progesterone.

Estrogen and progesterone replacement therapies are provided herein. Among others, the following formulations are provided herein: solubilized estradiol without progesterone; micronized progesterone without estradiol; micronized progesterone with partially solubilized progesterone; solubilized estradiol with micronized progesterone; solubilized estradiol with micronized progesterone in combination with partially solubilized progesterone; and solubilized estradiol with solubilized progesterone.